ANAVEX LIFE SCIENCES CORP.
No SEC Form 4 filings for $AVXL in the last 30 days.
See all $AVXL insider activity →ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome Anavex now has open INDs in all three core indications: Alzheimer’s disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and ph
Anavex Life Sciences (AVXL) received FDA clearance to proceed with a Phase 2a study of blarcamesine for Fragile X syndrome, a condition with no FDA-approved treatments. The study will evaluate the drug's safety, tolerability, and pharmacokinetics in about 60 adult males.
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.01 Changes in Control of Registrant. As further described under Item 5.07 of this Current Report on Form 8-K, Anavex Life Sciences Corp. (“Anavex” or the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on September 24, 2026. The election of t
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning AVXL (ANAVEX LIFE SCIENCES CORP.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.
Recent AVXL coverage spans financial news, earnings and regulation.
IND clearance removes a key regulatory gating item and allows Anavex to proceed with site activation and enrollment for its FXS Phase 2a program.
FDA clearance to proceed with the Fragile X IND is a concrete regulatory step that enables the planned Phase 2a trial, reducing execution risk versus a stalled IND.
The vesting may increase share supply and dilute existing shareholders, creating modest downside pressure.
Extended cash runway reduces near-term financing risk; FDA IND submission signals upcoming pivotal trial design discussions.
Profitability and pipeline progress may boost sentiment.
AlphAI scores every news story that mentions AVXL with an AI model for sentiment and relevance, and aggregates insider trades from ANAVEX LIFE SCIENCES CORP.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome Anavex now has open INDs in all three core indications: Alzheimer’s disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and ph
3 min readAnavex Life Sciences (AVXL) received FDA clearance to proceed with a Phase 2a study of blarcamesine for Fragile X syndrome, a condition with no FDA-approved treatments. The study will evaluate the drug's safety, tolerability, and pharmacokinetics in about 60 adult males.
4 min readANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.01 Changes in Control of Registrant. As further described under Item 5.07 of this Current Report on Form 8-K, Anavex Life Sciences Corp. (“Anavex” or the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on September 24, 2026. The election of t
1 min readAnavex Life Sciences (AVXL) is advancing Alzheimer's Phase 3 planning with the FDA and reported $118.3M in cash, extending its runway into fiscal 2028. The company is focusing on blarcamesine for Alzheimer's, Rett syndrome, and Fragile X syndrome. It expects to submit a Fragile X IND in September and seeks FDA agreement to include pediatric patients in its Rett syndrome Phase 3 trial.
3 min readTenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.
3 min readAnavex Life Sciences (AVXL) reported Q3 2026 net income of $7.8M, reversing a prior-year loss, driven by expense recoveries. Cash reserves total $118.3M. The company advanced its lead drug, Blarcamesine, in Alzheimer's, Rett, and Fragile X trials, with FDA discussions planned.
2 min readANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer’s
2 min readAnavex Life Sciences (NASDAQ:AVXL) filed definitive proxy materials for a Sept. 24, 2026 annual meeting, where a contested board election will pit Anavex’s six nominees against PVG Asset Management’s slate. Anavex says PVG holds 0.35%. The vote coincides with FDA engagement on blarcamesine in Alzheimer’s and Rett, plus Fragile X, and a Nasdaq delinquency over a late March 10-Q.
5 min readANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update Establishing Disciplined, Data-Driven Strategy with Focus on FDA Engagement for Alzheimer’s Disease New York, NY, July 30, 2026 - Anavex Life Sciences Corp. (A
4 min readThe Second Circuit affirmed dismissal of a securities fraud suit against Anavex Life Sciences Corp. in Huey v. Anavex, ruling the plaintiff failed to plausibly plead loss causation. The stock rose 5.8% on the corrective disclosure day, then fell 7.0% and 4.8% over two days, tracking the broader market, according to the court.
4 min read
